Chiasma Inc. (NASDAQ:CHMA) has been assigned an average broker rating score of 3.00 (Hold) from the three brokers that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a hold recommendation. Chiasma’s rating score has declined by 20% in the last 90 days as a result of various analysts’ ratings changes.
Brokers have set a one year consensus price objective of $4.75 for the company and are expecting that the company will post ($0.73) EPS for the current quarter, according to Zacks. Zacks has also assigned Chiasma an industry rank of 92 out of 265 based on the ratings given to related companies.
Chiasma (NASDAQ:CHMA) opened at 2.84 on Monday. Chiasma has a 12-month low of $2.40 and a 12-month high of $24.78. The stock has a 50 day moving average of $2.68 and a 200 day moving average of $4.33. The firm’s market cap is $69.17 million.
Chiasma (NASDAQ:CHMA) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.47. On average, equities research analysts anticipate that Chiasma will post ($3.14) EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of CHMA. MPM Asset Management LLC increased its position in shares of Chiasma by 1.0% in the second quarter. MPM Asset Management LLC now owns 5,736,296 shares of the company’s stock worth $16,578,000 after buying an additional 54,752 shares during the period. Wellington Management Group LLP increased its position in shares of Chiasma by 1,074.0% in the first quarter. Wellington Management Group LLP now owns 1,245,265 shares of the company’s stock worth $11,406,000 after buying an additional 1,139,195 shares during the period. Franklin Resources Inc. increased its position in shares of Chiasma by 32.5% in the first quarter. Franklin Resources Inc. now owns 807,440 shares of the company’s stock worth $7,396,000 after buying an additional 198,200 shares during the period. BlackRock Fund Advisors increased its position in shares of Chiasma by 4.5% in the first quarter. BlackRock Fund Advisors now owns 499,143 shares of the company’s stock worth $4,572,000 after buying an additional 21,384 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Chiasma by 25.7% in the second quarter. Vanguard Group Inc. now owns 426,477 shares of the company’s stock worth $1,233,000 after buying an additional 87,259 shares during the period. 58.76% of the stock is currently owned by hedge funds and other institutional investors.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.